What is the address of Dr. Sofie Demasure, oncoloog?

The registered office of Dr. Sofie Demasure, oncoloog is located at Veldstraat(Kor) 126, 8500 Kortrijk.

Is Dr. Sofie Demasure, oncoloog still active?

Yes. According to the CBE (19 September 2026) Dr. Sofie Demasure, oncoloog is active, legal situation “Normale toestand”, started on 12 July 2022.

Is Dr. Sofie Demasure, oncoloog registered on Peppol?

Yes, Dr. Sofie Demasure, oncoloog is registered on the Peppol network with ID 0208:0788497459.

What is the enterprise number of Dr. Sofie Demasure, oncoloog?

The enterprise number of Dr. Sofie Demasure, oncoloog is BE0788497459.

When was Dr. Sofie Demasure, oncoloog founded?

Dr. Sofie Demasure, oncoloog was founded on 12 July 2022.

Who are the directors of Dr. Sofie Demasure, oncoloog?

According to the 2025 annual accounts, the directors of Dr. Sofie Demasure, oncoloog are: SOFIE DEMASURE.

Is Dr. Sofie Demasure, oncoloog a reliable company?

Databakkes does not pass judgement; this is what the sources say: Active according to the CBE since 12 July 2022; 3 annual accounts filed, latest fiscal year 2025; 1 directors known from the annual account.

How much profit did Dr. Sofie Demasure, oncoloog make in 2025?

Dr. Sofie Demasure, oncoloog posted a profit after taxes of € 426,796 in financial year 2025.

What is the revenue of Dr. Sofie Demasure, oncoloog?

As a small company, Dr. Sofie Demasure, oncoloog is not required to publish revenue in its annual accounts. In financial year 2025, its added value was € 558,260.

Dr. Sofie Demasure, oncoloog (Private Limited) - Kortrijk

Dossier Dr. Sofie Demasure, oncoloog, printed on 19 September 2026 from databakkes.be/en/0788497459/dr-sofie-demasure-oncoloog. Sources: CBE, National Bank of Belgium, Belgian Official Gazette.

Financials

Financial year 2025

Dr. Sofie Demasure, oncoloog from Kortrijk, company number BE0788497459, closed financial year 2025 with a result of € 426,796 after tax. For that financial year Dr. Sofie Demasure, oncoloog recorded a gross margin of € 558,260 and equity of € 800,446. Compared with financial year 2024, the result moved from € 217,503 to € 426,796. Profitable, and profit is growing. The buffer is growing. A strong own buffer against the debts. The most recent annual accounts were filed with the National Bank of Belgium on June 30, 2026.

What it is worth Growing

€ 800,446

▲ 114% vs 2024

Assets minus debts, by the books. What is left if everything were sold and paid today.

Profit Growing

€ 426,796

▲ 96% vs 2024

Profit after tax over the fiscal year.

Cash in the bank

€ 497,467

▲ 140% vs 2024

Cash and bank balances on the last day of the fiscal year.

Where the profit goes Growing

Stays in the company

No dividend for 2025. Retained profit grew to € 797,446.

Debts at end 2025

Bank debt

None

No bank loans on the last day of the fiscal year.

Owed to suppliers

€ 566

Supplier invoices still open on the last day of the fiscal year.

Taxes

€ 54,834

▲ 3% vs 2024

Corporate tax and VAT still to pay. No wage debt: nothing outstanding to staff or social security.

Want to see how much further we take a dossier in the Pro version? Open the free De Lijn example and give feedback →

Key figures per fiscal year Download key figures (CSV)
	2023	2024	2025	Change 2024 → 2025
Gross margin	€ 224,591 Gross margin 2023: € 224,591 First fiscal year in the series	€ 315,142 Gross margin 2024: € 315,142 ▲ 40% vs 2023 (€ 224,591) Favourable step	€ 558,260 Gross margin 2025: € 558,260 ▲ 77% vs 2024 (€ 315,142) Favourable step	▲ 77%
Profit after taxes	€ 153,147 Profit after taxes 2023: € 153,147 First fiscal year in the series	€ 217,503 Profit after taxes 2024: € 217,503 ▲ 42% vs 2023 (€ 153,147) Favourable step	€ 426,796 Profit after taxes 2025: € 426,796 ▲ 96% vs 2024 (€ 217,503) Favourable step	▲ 96%
Equity	€ 156,147 Equity 2023: € 156,147 First fiscal year in the series	€ 373,651 Equity 2024: € 373,651 ▲ 139% vs 2023 (€ 156,147) Favourable step	€ 800,446 Equity 2025: € 800,446 ▲ 114% vs 2024 (€ 373,651) Favourable step	▲ 114%
Total debts	€ 58,254 Total debts 2023: € 58,254 First fiscal year in the series	€ 53,857 Total debts 2024: € 53,857 ▼ 8% vs 2023 (€ 58,254) Favourable step	€ 56,819 Total debts 2025: € 56,819 ▲ 5% vs 2024 (€ 53,857) Unfavourable step	▲ 5%
Cash	€ 213,316 Cash 2023: € 213,316 First fiscal year in the series	€ 207,010 Cash 2024: € 207,010 ▼ 3% vs 2023 (€ 213,316) Unfavourable step	€ 497,467 Cash 2025: € 497,467 ▲ 140% vs 2024 (€ 207,010) Favourable step	▲ 140%
Retained profit	€ 153,147 Retained profit 2023: € 153,147 First fiscal year in the series	€ 370,651 Retained profit 2024: € 370,651 ▲ 142% vs 2023 (€ 153,147) Favourable step	€ 797,446 Retained profit 2025: € 797,446 ▲ 115% vs 2024 (€ 370,651) Favourable step	▲ 115%
Balance sheet total	€ 214,402 Balance sheet total 2023: € 214,402 First fiscal year in the series	€ 427,507 Balance sheet total 2024: € 427,507 ▲ 99% vs 2023 (€ 214,402) Unchanged	€ 857,265 Balance sheet total 2025: € 857,265 ▲ 101% vs 2024 (€ 427,507) Unchanged	▲ 101%

Key figures of Dr. Sofie Demasure, oncoloog, fiscal years 2023 to 2025, from the annual accounts filed with the National Bank of Belgium.Next annual account (fiscal year 2026) expected before 31 July 2027.

What happened to Dr. Sofie Demasure, oncoloog?

What happened at Dr. Sofie Demasure, oncoloog in recent years, according to the Belgian Official Gazette, the CBE and the National Bank:

Jun 30, 2026 New annual accounts for financial year 2025: profit of € 426,796 (▲ 96% vs 2024). Source: NBB ↗
Jul 12, 2022 New establishment in Kortrijk. KBO
Jul 12, 2022 Start of the company according to the CBE. KBO

In short

From € 153,147 profit in 2023 to € 426,796 profit in 2025.

Paid € 297,964 in corporate taxes since 2023.

Best year ever: 2025, with € 426,796 profit.

Original PDFs at the National Bank ↗

A new publication or filing at Dr. Sofie Demasure, oncoloog? We notify you, reason included.

Follow Dr. Sofie Demasure, oncoloog

Databakkes Pro

Know what changes at your customers, suppliers and competitors. Without reading an annual account.

Follow them in one folder Every company in your folder gets this full dossier: household book, all fiscal years, benchmark against companies of the same size.
We alert you, with the reason New annual account, Official Gazette publication or status change: you get what changed and where it says so.
In bulk too, and in ChatGPT and Claude Upload your customer list and get the warning signs back per company. Or ask in your own AI assistant, with this register as the source.

Yes, I want that

See what a followed company gets: the De Lijn dossier

Databakkes Pro is being built. Sign up now and you are first in line for an invitation, with a month to try without a credit card.

My folder 3 companies

De Lijn 8 June 2026 New annual account 2025

filed on 8 June 2026

What was left

€ 20 k ▼ 91%
Money in the bank

€ 178 k ▼ 98%

Open the dossier →
NMBS 8 June 2026 New annual account 2025 What was left ▼ 80%
bpost 18 May 2026 New annual account 2025 What was left from loss to profit

Real filings at the National Bank

Management

SOFIE DEMASURE

Dr. Sofie Demasure, oncoloog

Behind Dr. Sofie Demasure, oncoloog is SOFIE DEMASURE.

See the full network in the app

Directors

According to the 2025 annual accounts

SOFIE DEMASURE

Director

Establishments

Establishment units

Physical locations of this company

Registered office

Veldstraat(Kor) 126

8500 Kortrijk

What is an establishment unit? An establishment unit is a geographically identifiable place where activities of the enterprise are carried out.

Details

Company number: 0788.497.459
VAT number: BE 0788.497.459
Registered office: Veldstraat(Kor) 126, 8500 Kortrijk
Names & denominations: Dr. Sofie Demasure, oncoloog
Enterprise type: Rechtspersoon
Legal form: Private limited company
Legal situation: Normale toestand
Start date: 12 July 2022
Peppol: Active · Active since 11 Dec 2024

View on CBE Public ↗ Annual accounts (NBB) ↗